A Phase 3 interventional study of Botulinum toxin A and bilateral medial rectus recession in Esotropia, sponsored by Jaeb Center for Health Research. Not yet recruiting. Open to participants aged 4 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment
Childhood esotropia (ET) is a common cause of visual disability, and its early management is critical for optimal visual and developmental outcomes.
The proposed study addresses a need to evaluate botulinum toxin A (BTX-A) as a less invasive, cost-effective alternative to incisional strabismus surgery. If BTX-A is demonstrated to be non-inferior to incisional strabismus surgery in treating ET >10 to ≤30PD, this could reduce surgical and anesthesia-related risks in infants, lower the economic burden on families and healthcare systems, and reduce disparities in access to care, particularly in underserved settings where surgical resources are limited.
After receiving informed consent, participants with ET >10 to ≤30PD who are otherwise eligible will be randomly assigned to treatment with BTX-A or incisional strabismus surgery; and seen 6 weeks, 6- and 12- months after surgery.
The primary outcome is the cumulative probability of motor alignment success by 12 months. Success is defined as the absence of failure by 12 months.
36 studies on the registry are indexed under Esotropia; 11 are open to participants now.
This study's planned enrollment of 244 is above the median of 78 across 23 interventional studies indexed under Esotropia.
Browse Esotropia studies →Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
A constant or intermittent ET needing intervention with BTX-A or surgery in the judgement of the investigator meeting one of the criteria below:
Infantile Esotropia (IET)
Acquired Non-accommodative Esotropia (ANAET)
Acquired Partially Accommodative Esotropia (APAET)
Age at enrollment:
Current Spectacle Correction at Time of Enrollment
Requirements for Spectacle Correction (if worn)
Group assigned to receive BTX-A injection
Drug: Botulinum toxin A
Group assigned to receive Graded bilateral medial rectus recession
Procedure: bilateral medial rectus recession
BTX-A 4.0 units to each medial rectus
Also known as: Botox
Graded bilateral medial rectus recession
Also known as: BMRrec
Motor Alignment Success
The primary efficacy outcome will be motor alignment success defined as follows: 1. Success is defined as the absence of failure by 1 year. 2. Failure is defined as any of the following post-randomized treatment (BOTOX or SURGERY) up to 1 year: * ET at distance (determined by a cover/uncover test) with a magnitude of \>10 PD by SPCT at or after the 6-month masked exam. * XT at distance at any time during the exam (determined by a cover/uncover test) with a magnitude of \> 10 PD by SPCT at or after the 6-month masked exam. * Second surgery or injection at any time after the initial surgery/injection through 12 months post-procedure.
Time frame: 1 Year
No study locations are listed for this record.
Plan to share: Yes — In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available after publication of each primary manuscript.
Access criteria: Users accessing the data must enter an email address.
Data sharing details ↗ · public.jaeb.org
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Jaeb Center for Health Research →